Skip to content
Screener

Janux Therapeutics JANX Restricted Cash

Restricted Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.2M-48.5%
Xencor logo
XencorXNCR
$191K-33.2%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$917K-10.8%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Immunome logo
ImmunomeIMNM
$210K0.0%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$316K-0.6%

Other financials

Income statement

See full
Revenue$10.3M—
Operating income-$31.7M+29.8%
Net income-$22.0M+35.1%
EPS (diluted)-$0.35+36.4%

Balance sheet

See full
Cash & equivalents$27.8M-47.1%
Total debt$21.0M-5.4%
Total equity$928.0M-6.3%
Total assets$1.0B-2.4%

Cash flow

See full
Operating cash flow$12.5M+152%
CapEx$202.0K-57.3%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$1B-26.4%
Enterprise value$996.48M-25.2%
P/S41.8×-3,061×

Profitability

See full
Operating margin-598.1%-296pp
Net margin-427.5%-212pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-10.7%-1.5pp
Debt / equity0×0.0×
Current ratio16.3×-30.7×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:18 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338078

FAQ

What is Janux Therapeutics's restricted cash?
Janux Therapeutics (JANX) reported restricted cash of $816K in Q2 2026.
How has Janux Therapeutics's restricted cash changed year-over-year?
Janux Therapeutics's restricted cash decreased by 0.0% year-over-year, from $816K to $816K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Janux Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude